Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study

Ling, Walter; Nadipelli, Vijay R; Solem, Caitlyn T; Ronquest, Naoko; Yeh, Yu-Chen; Learned, Susan M; Mehra, Vishaal; Heidbreder, Christian

doi:10.1097/adm.0000000000000517

Cited by 33 publications

(40 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RECOVER study (Remission from Chronic Opioid Use: Studying Environmental and SocioEconomic Factors on Recovery; NCT03604861)( Ling et al, 2019a ) was a 24-month, observational study that assessed life changes in patients with OUD who had received up to 12 monthly BUP-XR injections as part of either a separate randomized clinical efficacy trial (NCT02357901) ( Haight et al, 2019 ; Ling et al, 2019b ) and/or a separate open-label safety (NCT02510014) study before entering RECOVER. Additional details of the study design and characteristics of patients enrolled in the RECOVER study have been previously published ( Ling et al, 2019a ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

Ling

Nadipelli

Aldridge

et al. 2020

Journal of Addiction Medicine

Self Cite

View full text Add to dashboard Cite

Objectives: While evidence has mounted regarding the short-term effectiveness of pharmacotherapy for opioid use disorder (OUD), little is known about longer-term psychosocial, economic, and health outcomes. We report herein 12-month outcomes for an observational study enrolling participants who had previously taken part in a long-acting buprenorphine subcutaneous injection (BUP-XR) trial for moderate to severe OUD. Methods: The RECOVER (Remission from Chronic Opioid Use: Studying Environmental and SocioEconomic Factors on Recovery; NCT03604861) study enrolled participants from 35 US community-based sites. Self-reported sustained opioid abstinence over 12 months and self-reported past-week abstinence at 3-, 6-, 9-, and 12-month visits were assessed. Multiple regression models assessed the association of BUP-XR duration with abstinence, controlling for potential confounders. Withdrawal, pain, health-related quality of life, depression, and employment at RECOVER baseline and 12-month visits were also compared to values collected before treatment in the BUP-XR trial. Results: Of 533 RECOVER participants, 425 completed the 12-month visit (average age 42 years; 66% male); 50.8% self-reported sustained 12-month and 68.0% past-week opioid abstinence. In multiple regressions, participants receiving 12-month versus ≤2-month BUP-XR treatment duration had significantly higher likelihood of sustained opioid abstinence (75.3% vs 24.1%; P = 0.001), with similar results for past-week self-reported abstinence over time. During RECOVER, participants had fewer withdrawal symptoms, lower pain, positive health-related quality of life, minimal depression, and higher employment versus pre-trial visit. Conclusions: RECOVER participants reported positive outcomes over the 12-month observational period, including high opioid abstinence and stable or improved humanistic outcomes. These findings provide insights into the long-term impact of pharmacotherapy in OUD recovery.

show abstract

Section: Methodsmentioning

confidence: 99%

“…More recently, buprenorphine extended-release subcutaneous injection (BUP-XR a.k.a. RBP-6000 or SUBLOCADE, Indivior Inc, North Chesterfield, VA) was shown to be a safe and effective OUD treatment option ( Haight et al, 2019 ) that could improve the quality of life ( Ling et al, 2019b ) of treatment-seeking individuals with moderate or severe OUD.…”

mentioning

confidence: 99%

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

Ling

Nadipelli

Aldridge

et al. 2020

Journal of Addiction Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The higher dose was not superior to the lower dose. A secondary analysis of the study also indicated a higher satisfaction of patients in the depot groups with the therapy and a lower rate for hospital admissions [46].…”

Section: Rbp-6000 (Sublocade™)mentioning

confidence: 84%

“…Traveling and work may be much easier with a depot/implant compared to daily opioid administration. Negative aspects may be issues related to the surgical procedure, concerns for infection, fixed dosage regimen, and social isolation [46].…”

Section: Discussionmentioning

confidence: 99%

Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update

Soyka¹

2020

Pharmacopsychiatry

View full text Add to dashboard Cite

Opioid maintenance treatment with oral methadone or sublingual buprenorphine is the first-line treatment in opioid dependence. Three novel long-acting buprenorphine formulations have been approved or will be available soon: for subcutaneous weekly and monthly application, the depot formulations CAM 2038 (Buvidal®), the monthly depot formulation RBP-6000 (Sublocade™), and a 6-month buprenorphine implant (Probuphine™). Clinical data available so far on the efficacy of these 3 medications are given, and possible clinical implications are discussed.

show abstract

“…1. To ensure the safety of patients, "Everything is patient-centered" is the primary core concept of JCI, which has become the consensus of many hospitals and is also one of the purposes and footholds of hospital management [8]. We summarize the needs of patients into four elements: "quaesitum, solicitude, surroundings, and expenditure ", in another word, "effect, care, cost, and environment."…”

Section: Innovation Of Hospital Management Mode--double Qsse Hospitalmentioning

confidence: 99%

Double QSSE innovative hospital management model based on JCI standard and its application in private hospital in China

Zong

Zheng

2020

Preprint

View full text Add to dashboard Cite

BackgroundThe Joint Commission on International Accreditation of Health Care Organizations (JCI) standard is a hospital accreditation standard recognized by the medical industry worldwide. However, the previous Chinese hospital management model cannot be fully integrated with the JCI standard. The purpose of this study is to explore a new Chinese hospital management mode that adapts to JCI standard.MethodsThis article retrospectively analyzed the initial results of the operation of the double QSSE management mode at Xuzhou Renci Hospital, a Chinese private hospital from 2016 to 2018. The innovation mode combines the four elements of patients' needs "Quaesitum, Solicitude, Surroundings, and Expenditure" with the four core contents of hospital management "Quality, Service, Staff and Economic operation".ResultsAfter two years implementation of the model, Xuzhou Renci hospital has reached a series of achievements, including being elected as the honest private hospitals and ranking first, achieved the highest grade of "special satisfaction" in the third-party hospital satisfaction survey organized by the government; being rated as "the most beautiful hospital in China" and awarded the title of "the most beautiful hospital in China—the light of the city"; promoted to the third-grade orthopedic hospital in 2019; ranked in the forefront of original non-public hospitals in northern Jiangsu Province in the Chinese hospital competitiveness conference hosted by Asclepius Health in Hong Kong 2019; recognized as the "safe demonstration hospital" in Jiangsu Province 2019.ConclusionThe double QSSE refined management mode has the characteristics of standardization, quantification, comparison, easy assessment and easy replication, which improves not only the patient-centered medical experience, but also the hospital-department quality management system. It is an innovative hospital management mode that conforms to JCI standard and adapts to China's national conditions.

show abstract

Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study

Abstract: Supplemental Digital Content is available in the text

Cited by 33 publications

References 15 publications

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update

Double QSSE innovative hospital management model based on JCI standard and its application in private hospital in China

Contact Info

Product

Resources

About